Navigation Links
Phase 1 Trial of Quadramet in Combination with Velcade Shows Positive Results
Date:2/11/2009

EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma.

LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets the bone, specifically bone cancer, and is used to treat pain caused by cancer that has metastasized or spread to the bone. Velcade (bortezomib) is approved for the treatment of multiple myeloma alone and in addition to chemotherapy. Preclinical studies have reported that the combination of Velcade with Quadramet is much more effective than either drug alone in its anti-myeloma effects.

Published in the journal Clinical Cancer Research, this US-based Phase 1 study included 39 multiple myeloma patients at three clinical oncology sites. Noted oncologist and myeloma specialist, Dr. James R. Berenson was Principal Investigator.

The Phase 1 study evaluated the combination of radiotherapy, a drug that targets bone and bone marrow, with Velcade in order to determine efficacy and safety among patients who had been previously treated. This groundbreaking study marks the first attempt to evaluate targeted radiotherapy with the potent myeloma drug Velcade for myeloma patients.

Dr. Berenson reports, "By using less Velcade than in previous studies along with Quadramet, responses were observed even among patients who were failing Velcadebased therapy. Some patients achieved complete responses with this novel combination treatment in this Phase 1 study. Patients were given 4 doses of Velcade every 8 weeks instead of the standard 4 doses every 3 weeks, and we observed much less peripheral neuropathy with this less intensive schedule. Overall this was a very well tolerated treatment for the patients."

James R. Berenson, MD is a 25 year veteran in the field of oncology wi
'/>"/>

SOURCE Oncotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... YORK , Sept. 2, 2015   About ... the most common laboratory technologies that is used for ... antibodies in solution. ELISA test uses various types of ... phosphatases and the result is detected by photometry or ... the treatment of various infectious diseases such as HIV, ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015 STAAR Surgical ... marketer of implantable lenses and delivery systems for the eye, ... William P. Wall to the Company,s Board. ... Capital, a Boston -based investment firm, for ... of the Board of Directors, and chair of the Corporate ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
Breaking Medicine Technology:Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
(Date:9/3/2015)... ... September 03, 2015 , ... Representatives with ... at the highly anticipated Mississippi Gulf Babypalooza on September 19, 2015. , “We ... from Gulfport, Biloxi, and beyond. We will be discussing setting up college funds, ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen an ... health care model, where the primary care physician dictates and the patient obeys. Instead, ... educated about their health issues and empowered to choose their own treatment options. , ...
(Date:9/3/2015)... ... September 03, 2015 , ... About 220,800 new cases of prostate cancer are reported each year, ... diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically ... by age 65, according to the American Cancer Society. , Prostate ...
(Date:9/3/2015)... ... September 03, 2015 , ... James Earl Jones will ... wellness. In this episode, James Earl Jones will introduce a segment that discusses why ... workplace and how workplace wellness can be fostered in any working environment. , Employers ...
(Date:9/3/2015)... FLORIDA (PRWEB) , ... September 03, 2015 , ... ... of the highest-regarded health professionals out there. His perspective on internal medicine keeps patients ... stay happy and healthy is important regardless of the season, but even more so ...
Breaking Medicine News(10 mins):Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2
... Eli Lilly and Company (NYSE: LLY ) today declared a ... outstanding common stock. This is the same dividend as was paid ... rate for 2009 of $1.96 per share. , , The ... close of business on August 15, 2009. , , About Lilly ...
... blames physician misdiagnosis as the likely cause of apparent uptick ... A newly released study in the June 2009 British Journal ... the eastern United Kingdom has concluded that the much-hyped melanoma ... The study attributed the increase in melanoma diagnoses to heightened ...
... Now there,s a new reason for the,weight-conscious to drink fat ... the July issue of the American Journal of Clinical,Nutrition. Researchers ... helped increase satiety, or a feeling of fullness, and lead ... a fruit drink. The,milk drinkers ate about 50 fewer calories ...
... Personalized Medicine Meeting Elicits Varying Perspectives , , WASHINGTON, ... to regulate genetic testing is problematic, according to a recent ... of the attendees at a colloquium on personalized medicine, sponsored ... American Association for the Advancement of Science (AAAS) responded "yes" ...
... to attend field hearing exploring use of Recovery Act funds ... Senator Benjamin L. Cardin (D-MD ), chaired a field hearing ... Entrepreneurship in Rockville, MD, entitled " Missed Opportunities: The ... local and national experts in biotechnology testified about the important ...
... Center,s two camps, Camp Courage in Maple Lake and Courage North ... people with disabilities. , , A recent Muscular Dystrophy camp ... MDA staff) who tested positive for H1N1 flu (also known as ... officials were contacted by the MDA locally three days after the ...
Cached Medicine News:Health News:New Study Says Purported Melanoma Epidemic is Vastly Overstated 2Health News:Drinking Milk in the Morning May Help Stave off Lunchtime Hunger 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3Health News:Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 2Health News:Courage Camps Maintain Summer Camp Schedule for Children and Adults With Disabilities 2
Rapid Test Kit...
... Advanced Vision Information System) is an open ... on a platform designed to communicate and ... network can be expanded in various ways, ... Nidek products but also to fundus cameras ...
... laser photocoagulators includes the OcuLight SL and ... as a single laser source for multiple ... maintenance or special electrical/cooling, and allow easy ... SLx is now available with Tri-Mode capability ...
The simplest, most accurate Ortho-K lens fitting system ever!...
Medicine Products: